HBM Healthcare Investments AG / Keyword (s): Obligation

15-Jun-2021 / 07:00 CET / CEST
Publication of an ad hoc announcement in accordance with art. 53 crowns
The issuer is solely responsible for the content of this advertisement.

HBM Healthcare Investments Ltd announces the issue of a bond issue with a maturity of 6 years and a nominal amount of CHF 60 million with the possibility of increasing the amount of the issue up to a maximum of CHF 75 millions. The proceeds will be used to refinance the bond due July 10, 2021 up to CHF 50 million and for general financing purposes.

Helvetische Bank AG and Raiffeisen Switzerland Cooperative as Joint Lead Managers and Reichmuth & Co as Co-Lead Manager have firmly subscribed to the obligation. The terms are as follows:

Transmitter

HBM Healthcare Investments SA, Zug, Switzerland

Issue amount

CHF 60’000’000
with the possibility of increasing the amount up to a
maximum of CHF 75,000,000

Coupon

[1⅛-1⅝]% pa

Term

6 years

Issue price

100%

Redemption

100%

Date of issue

July 12, 2021

Trading / Listing

Provisional admission to trading on SIX Swiss
Exchange scheduled from July 9, 2021; thereafter definitive
listing and admission to trading will be requested.

The final conditions (issue amount and coupon) will be set and communicated based on demand in the book building and general market conditions no later than June 18, 2021 after market close. The book building can be terminated at any time by the Joint Lead Managers.

HBM Healthcare Investments and its Investment Advisor HBM Partners have agreed that no management fee will be due on the financial debt raised by the issuance of this bond.

Contact
For more information, please contact Dr Andreas Wicki on +41 41 710 75 77, or [email protected].

About HBM Healthcare Investments

HBM Healthcare Investments invests in the healthcare sector. The Company owns and manages an international portfolio of promising companies in the sectors of human medicine, biotechnology, medical technology and diagnostics and related fields. Many of these companies have their flagship products already available in the market or at an advanced stage of development. The portfolio companies are closely monitored and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an attractive alternative to investments in large pharmaceutical and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on the SIX Swiss Exchange (ticker: HBMN).

Warning

The publication is for informational purposes only and does not constitute an offer to sell or a solicitation to buy or subscribe to any bonds or any other security of HBM Healthcare Investments Ltd. This press release does not constitute a prospectus within the meaning of the Swiss Financial Services Law (“FinSA”) and implementing provisions of the Swiss Financial Services Ordinance (“FinSO”) nor a listing prospectus within the meaning of the Regulations. listing of SIX Swiss Exchange SA or a prospectus in accordance with any other legislation or regulation. The decision to buy or subscribe to bonds must be taken solely on the basis of the relevant prospectus. The provisional prospectus and the final prospectus both published in German for the bonds (which should be available on June 15, 2021 and June 18, 2021 respectively) can be ordered free of charge by e-mail from Helvetische Bank AG at prospectus @ helvetischebank .ch or by calling +41 (0) 44 204 56 19.

This press release does not constitute a prospectus or an additional prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017 (the “EU Prospectus Regulation”) or of the EU Prospectus Regulation as stated in it is part of domestic law under the European Union (Withdrawal) Act 2018 (the “UK Prospectus Regulation”). This press release is intended for and directed only to qualified investors from any member state of the European Economic Area within the meaning of the EU Prospectus Regulation. The Bonds are not intended to be offered, sold or otherwise made available and should not be offered, sold or otherwise made available to a retail investor in the European Economic Area.

This press release is addressed only to persons who are qualified investors within the meaning of the UK Prospectus Regulations and who (i) have professional experience in matters relating to investments falling under Section 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are persons falling under Section 49 (2) (a) to (d) (high net worth companies, unincorporated associations, etc. .) of the Financial Services and Markets (Financial Promotion) Act 2000 Ordinance 2005 (as amended) or to whom it may be legally communicated (all such persons being together referred to as affected persons). The Bonds are not intended to be offered, sold or otherwise made available and should not be offered, sold or otherwise made available to any UK retail investor. This press release is addressed to data subjects only and should not be used or relied on by persons who are not data subjects. Any investment or investment activity to which this communication relates is accessible only to the persons concerned and will only be undertaken with the persons concerned.

NEITHER THIS DOCUMENT NOR ANY PART OR COPY OF IT NOR THE INFORMATION CONTAINED IN IT AND ANY RELATED DOCUMENTS MAY BE TAKEN OR TRANSMITTED IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY INVESTOR OF RETAIL IN THE EEA OR DISTRIBUTED OR REDISTRIBUTED, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, TO ANY RETAIL INVESTOR IN THE EEA OR THE UNITED KINGDOM OR TO ANY RESIDENT OF THIS ONE. constitute an offering of securities in the United States. Neither this press release nor any copy of it may be taken or transmitted in the United States, its territories or possessions, or distributed, directly or indirectly, in the United States, its territories or possessions, or to any American person such as defined in Regulation S (“Regulation S”) under the US Securities Act 1933, as amended (the “Securities Act”). Any breach of this restriction may constitute a violation of US securities law. Accordingly, each person viewing this document will be deemed to have declared that they are not a US Person within the meaning of Regulation S of the Securities Act. Securities may not be offered or sold in the United States without registration or an exemption from registration. HBM Healthcare Investments Ltd has not registered and does not intend to register any securities that may be described herein in the United States or to make a public offering of securities in the United States.

This document does not constitute an offer of securities to be sold or purchased in the United States. The securities to which this document relates have not been and will not be registered under the Securities Act, and may not be offered or sold in the United States absent registration or an exemption from registration in under the Securities Act. There will be no public offering of securities in the United States.

This document was prepared by HBM Healthcare Investments Ltd. and may not be copied, modified, offered, sold or otherwise given to third parties by the recipient without the consent of HBM Healthcare Investments Ltd. The German version of the document is applicable and binding in any event. Versions of the document in other languages ​​are provided for informational purposes only. Every precaution has been taken to ensure that the facts set forth here are correct and that all opinions expressed herein are fair and reasonable. Certain information cited was obtained from external sources which HBM Healthcare Investments Ltd considers reliable. HBM Healthcare Investments Ltd cannot guarantee the adequacy, correctness, timeliness or completeness of any errors of fact concerning such data and information obtained from third parties. parts, and this data may change with market conditions. The facts and information presented in this document are as current as possible but may change in the future. HBM Healthcare Investments Ltd as such and its directors, officers, employees and advisers or any other person disclaim any express or implied liability or warranty as to the accuracy or completeness of the information contained in this document.

This document may contain projections or other forward-looking statements relating to HBM Healthcare Investments Ltd that involve inherent risks and uncertainties, both general and specific, and there is a risk that the projections, forecasts, plans and other explicit contents or implied by forward-looking statements may prove to be inaccurate. All forward-looking statements are based on information available to HBM Healthcare Investments Ltd at the date of their publication; HBM Healthcare Investments Ltd is only obligated to update these statements as required by applicable law.

End of ad hoc announcement



Source link

Leave a Reply

Your email address will not be published.